FDAは,より多くの体重減少を必要とする肥満の成人に高用量Wegovy (7. 2 mg) を承認し,試験では平均19%の減量を示した. The FDA approved a higher-dose Wegovy (7.2 mg) for obese adults who need more weight loss, showing 19% average weight reduction in trials.

FDAは,2. 4mgの投与量を許容し,さらに体重を減らす必要がある肥満成人向けに,4月により高用量版 (7. 2 mg) のWegovyを承認しました. The FDA has approved a higher-dose version of Wegovy (7.2 mg), now available in April, for adults with obesity who’ve tolerated the 2.4 mg dose and need further weight loss. 臨床試験では,より高い用量により17ヶ月間にわたって体重が平均19%減少し,低用量の場合は16%減った. 31%は少なくとも25%の体重減少を達成した. Clinical trials showed the higher dose led to an average 19% body weight loss over 17 months, compared to 16% on the lower dose, with 31% achieving at least 25% weight loss. 薬は食事と運動と共に使用され,吐き気や嘔吐,便秘,皮膚の灼熱感などの副作用がより頻繁に発生しました. The drug is used with diet and exercise, and side effects including nausea, vomiting, constipation, and a burning skin sensation occurred more frequently. 深刻な副作用は,使用者のほぼ7%で報告された. Serious adverse events were reported in nearly 7% of users. 欧州の規制当局は2月にすでにより高い用量に承認していた. European regulators had already approved the higher dose in February. 価格の詳細は待機中です. Pricing details are pending.